**Name of journal: World Journal of Diabetes**

**ESPS Manuscript NO: 1694**

**Columns: TOPIC HIGHLIGHT**

Vascular endothelial growth factor trap-eye (Aflibercept) for the management of diabetic macular edema

Moradi A *et al*. Aflibercept for DME

Ahmadreza Moradi, Yasir Jamal Sepah, Mohammad Ali Sadiq, Humzah Nasir, Salima Kherani, Raafay Sophie, Diana V Do, Quan Dong Nguyen

**Ahmadreza Moradi, Yasir Jamal Sepah, Mohammad Ali Sadiq, Humzah Nasir, Salima Kherani, Raafay Sophie, Diana V Do, Quan Dong Nguyen,** Retinal Imaging Research and Reading Center, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, United States

**Yasir Jamal Sepah, Diana V Do, Quan Dong Nguyen,** Stanley M Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, NE 68198, United States

**Author contributions:** All authors contributed equally to this work.

**Correspondence to: Quan Dong Nguyen, MD, MSc**, Stanley M Truhlsen Eye Institute, University of Nebraska Medical Center, Emile St, Omaha, NE 68198, United States. quan.nguyen@unmc.edu

**Telephone:** +1-402-5594276  **Fax:** +1-402-5595514

**Received:** December 27, 2012 **Revised:** May 31, 2013

**Accepted:** June 18, 2013

**Published online:**

**Abstract**

Diabetic retinopathy (DR) is the most common cause of visual loss among working age individuals. Diabetic macular edema (DME) is an important complication of DR that affects around one third of the patients with DR. Several treatments have been approved for DME ranging from blood pressure and glycemic control to photocoagulation and more recently the use of vascular endothelial growth factor (VEGF) antagonists. The index review discusses aflibercept (EYLEA®- Regeneron Pharmaceuticals, Inc., Tarrytown, New York, NY, and Bayer Healthcare Pharmaceuticals, Berlin, Germany) in the context of other VEGF antagonists currently available for the treatment of DME. A systematic search of literature was conducted on PubMed, Scopus, and Google Scholar with no limitation on language or year of publication. Pre-clinical studies of aflibercept have shown a higher affinity of this molecule for vascular endothelial growth factor A (VEGF-A) along with a longer duration of action as compared to other VEGF antagonists. Recent clinical trials have shown visual outcome results for aflibercept to be similarly favorable as compared to other available agents with the added benefit of fewer required injections and less frequent monitoring. Aflibercept presents a potential exciting new addition to the armamentarium of current VEGF antagonists available for the treatment of DME and other retinal vascular diseases. However, further studies are indicated to confirm the role, safety, and efficacy of aflibercept for DME.

© 2013 Baishideng. All rights reserved.

**Key words:** Diabetic macular edema; Diabetic retinopathy; Anti vascular endothelial growth factor agents; Vascular endothelial growth factor Trap-Eye; Aflibercept; EYLEA

**Core tip:** Several different agents have been approved recently for the treatment of diabetic macular edema (DME). The index article outlines the role of aflibercept, an anti-vascular endothelial growth factor (VEGF) agent, as a potential therapeutic option. Results from DME trials with aflibercept have been favorable and comparable to other anti-VEGF agents. Because of its longer half-life, aflibercept may also decrease the frequency of injections for DME patients. These results could be attributed to the stronger and prolonged binding of aflibercept to the VEGF-A receptor compared to other available antagonists. A better understanding of the effect of this drug in DEME is expected once the phase 3 trial results are available.

Moradi A, Sepah YJ, Sadiq MA, Nasir H, Kherani S, Sophie S, Do DV, Nguyen QD. Vascular endothelial growth factor trap-eye (Aflibercept) for the management of diabetic macular edema.

**Available from: URL:**

**DOI:**

**INTRODUCTION**

In recent years, the rise in the incidence of diabetes mellitus (DM) has been accompanied by a significant increase in the incidence of its microvascular complications, including diabetic retinopathy[1].Diabetic retinopathy (DR) is the most common cause of visual loss in working age individuals in developed nations[[2](#_ENREF_2),[3](#_ENREF_3)] Complications of diabetic retinopathy include: cataract, glaucoma, macular edema (ME), retinal hemorrhage and retinal detachment, among others.

Approximately one third of DR patients have ME while overall ME affects around 7.5% of diabetic population[[4](#_ENREF_4)].

Over the years the treatment of DR has ranged from tight glycemic control to partial pituitary destruction and it was not until the Early Treatment Diabetic Retinopathy Study (ETDRS) showed efficacy of laser in treating DR/DME that this modality was recognized as a useful intervention. It was demonstrated that laser photocoagulation can reduce the risk of moderate visual loss by 50% three years after initiation of treatment and was thus approved for the treatment of DME[[5](#_ENREF_5)]. However, this form of treatment often prevents further visual loss and rarely results in improvement of vision. Therefore, researchers have explored newer therapies to improve treatment outcomes for patients with DME[[6](#_ENREF_6),[7](#_ENREF_7)].

**RATIONALE FOR CONSIDERING VEGF ANTAGONISTS FOR DME**

DME results from microvascular changes secondary to hyperglycemia and the inflammatory changes associated with diabetes. These include thickening of the basement membrane and loss of pericytes, which leads to increased permeability of vessels leading to edema formation. Associated hypoxia due to vascular occlusion also leads to the release of several cytokines such as vascular endothelial growth factor (VEGF), insulin-like growth factor-1, angiopoeitin-1 and -2, stromal-derived factor-1, fibroblast growth factor-2, and tumor necrosis factor[[8](#_ENREF_8)].

In 1994 Aiello *et al*[[9](#_ENREF_9" \o "Aiello, 1994 #837)] demonstrated that VEGF levels are elevated in the ocular fluid of patients with diabetic retinopathy and other retinal disorders, including DME. Subsequently, Ozaki *et al*[[10](#_ENREF_10" \o "Ozaki, 1997 #840)] and Tolentino *et al*[[11,12](#_ENREF_10)] showed that intravitreal injection of VEGF in nonhuman primates could generate similar findings of diabetic retinopathy such as micro aneurysms, macular edema, and retinal neovascularization. Recent studies have also confirmed that hypoxia-induced VEGF release has a key role in the pathophysiology of DME[[13](#_ENREF_13" \o "Nishikiori, 2007 #841)]. During the past decade, the scientific community has learned that VEGF leads to neovascularization, increased vascular permeability and breakdown of the blood retina barrier, leading to the formation of ME[[14](#_ENREF_14)].

The establishment of the VEGF pathway leading to ME in patients with diabetes and age-related macular degeneration (AMD) led to the development of anti VEGF therapies that are briefly discussed below.

**VEGF ANTAGONISTS THAT HAVE BEEN EVALUATED FOR DME**

Pegaptanib sodium (Macugen, Eyetech Pharmaceuticals, Melville, NY/Pfizer, New York, NY) is an anti-VEGF aptamer that blocks the effect of VEGF by binding to the VEGF-A165 isoform. It was the first U.S Food and Drug Authority (FDA) approved anti VEGF agent for treatment of choroidal neovascularization (CNV) resulting from AMD[[15](#_ENREF_15),[16](#_ENREF_16)]

Cunningham *et al*[[17](#_ENREF_17)] demonstrated in a double-masked phase 2 trial that subjects with DME who were assigned to the pegaptanib arm had better visual acuity (VA) outcomes [a larger proportion of those receiving 0.3 mg gained VAs of ≥ 10 letters as compared to the sham group (34% *vs* 10%, *P =* 0.003) and ≥ 15 letters (18% *vs* 7%, *P =* 0.12)], were more likely to show reduction in central retinal thickness [Mean central retinal thickness decreased by 68 μm with 0.3 mg, *vs* an increase of 4 μm with sham (*P =* 0.02)], and were deemed less likely to need additional therapy with photocoagulation at follow-up as compared to sham injections at week 36. Phase 3 trials are currently underway[[18](#_ENREF_18)].

Ranibizumab (Lucentis™, Genentech, San Francisco, CA) is a humanized antibody fragment that binds to all isoforms of VEGF-A. In 2006, Nguyen and colleagues were among the first clinician-scientists in the world to demonstrate that VEGF plays a critical role in the pathogenesis of DME and that employment of a VEGF antagonist such as ranibizumab may help to reduce retinal edema[[19](#_ENREF_19)]. The READ-2 study, a phase II, randomized clinical trial, was conducted to evaluate the efficacy of ranibizumab for DME. Subjects were randomized 1:1:1 to receive 0.5 mg ranibizumab (group 1), focal or grid laser photocoagulation (group 2), or a combination of laser and ranibizumab (group 3). After the primary end point at month 6, at the discretion of the investigators, the majority of patients were treated only with ranibizumab. The mean improvement in BCVA was 7.24, 0.43, and 3.8 letters at the 6-month primary end point[[20](#_ENREF_20" \o "Nguyen, 2009 #77)], compared with 7.7, 5.1, and 6.8 letters at month 24. Mean foveal thickness (FTH), defined as center subfield thickness, at month 24 was 340 μm, 286 μm, and 258 μm for groups 1, 2, and 3, respectively[[21](#_ENREF_21" \o "Nguyen, 2010 #845)]  
 The RISE and RIDE studies, two randomized, multicenter and double masked phase 3 trials, have shown that ranibizumab improved vision and macular edema in patients with DME and reduced the risk of further visual loss. The results of the RISE study showed that 18.1% of sham patients gained ≥ 15 letters *vs* 44.8% of 0.3-mg (*P <* 0.0001) and 39.2% of 0.5-mg ranibizumab patients (*P <* 0.001). In RIDE, 12.3% of sham patients gained ≥ 15 letters *vs* 33.6% of 0.3-mg patients (*P <* 0.0001) and 45.7% of 0.5-mg ranibizumab patients (*P <* 0.0001). Based on such significant results from RISE and RIDE, the FDA approved ranibizumab for DME in August 2012[[22](#_ENREF_22)] .

Bevacizumab (Avastin®, Genentech, San Francisco, CA) is a full-length recombinant humanized antibody that targets all isoforms of VEGF-A. It is approved by the FDA as adjunctive treatment for metastatic colonic cancer but has not yet been approved for ocular diseases. The intravitreal Bevacizumab or Laser Therapy in the Management of Diabetic Macular Edema (BOLT) study, which was conducted on patients with center-involving clinically significant macular edema (CSME), showed a mean gain of 8.6 letters in the bevacizumab group as compared to a mean loss of 0.5 letters for the macular laser therapy group[[23](#_ENREF_23)].

Table 1 outlines a summary of landmark clinical trials in which VEGF antagonists were evaluated for DME.

**INTRODUCTION TO VEGF TRAP EYE/AFLIBERCEPT**

VEGF Trap-Eye/Aflibercept (EYLEA®- Regeneron Pharmaceuticals, Inc., Tarrytown, New York, NY, and Bayer Healthcare Pharmaceuticals, Berlin, Germany) is a novel 115-kDA anti-VEGF agent. This fusion protein has been developed using the “trap technology” in which the extracellular binding domains of VEGF receptor (VEGFR) -1 and -2 are combined to the Fc segment of human immunoglobulin-G1 backbone[[24](#_ENREF_24)]. Similar to ranibizumab and bevacizumab, aflibercept binds to all isomers of the VEGF-A family. Additionally, aflibercept binds to VEGF-B and placental growth factor; it is hypothesized that by blocking these factors, aflibercept may prove to be more efficacious[[25](#_ENREF_25)].

As a soluble circulation trap for VEGF, aflibercept binds firmly to the target, clears it out from the vitreous[[26](#_ENREF_26)], and consequently inhibits binding and activation of the VEGF receptors. The affinity of aflibercept to VEGF-A is much higher than monoclonal anti-VEGF antibodies (5 pM kD *vs* 1 pM kD).

The receptor sequences of aflibercept provide powerful VEGF binding (140 times that of ranibizumab) and the molecule's intermediate size of 110 kD (compared to 48 kD for ranibizumab and 148 kD for bevacizumab) creates a one-month intravitreal binding activity that exceeds both ranibizumab and bevacizumab[[27](#_ENREF_27)].

According to Stewart *et al*[[27](#_ENREF_27)], a predictive model showed that aflibercept is active in the eye for 10 to 12 wk after a single intravitreal injection, with the binding activity of 2 mg VEGF Trap-Eye at 83 d estimated to be comparable to that of 0.5 mg ranibizumab at 30 d.

The half-life of intravitreally-administered aflibercept in animals is about 5 d; however, the half-life in the human eye has not yet been identified. Based on a mathematical model, this half-life is estimated to be about 7.13 d[[28](#_ENREF_28),[29](#_ENREF_29)].

***Dosage and safety***

Aflibercept is available in a single-use vial which contains 0.05 mL of aflibercept (40 mg/mL in 10 mmol/L sodium phosphate, 40mM sodium chloride, 0.03% polysorbate 20, and 5% sucrose, pH 6.2) {[30](#_ENREF_30)]. To date, aflibercept is only available for intravitreal (IVT) injection. Although intravenous administration of doses ≥ 1 mg/kg has caused some systemic adverse events, no systemic effects have been reported in any phase-I, phase-II, or phase-III trials with IVT administration of doses of up to 4 mg (< 0.06 mg/kg;0.057 mg/kg)[[31-33](#_ENREF_31)].

**AFLIBERCEPT FOR DME: CURRENT EVIDENCE**

In 2009, a phase-I study was conducted by Do *et al*[31] to assess the safety, tolerability and bioactivity of a single 4mg intravitreal injection of aflibercept in five patients with DME over a period of six weeks. Participants older than 18 years with type 1 or type 2 diabetes, retinal thickening involving the foveal center due to DME, foveal thickness ≥ 250 µm as measured by Stratus OCT, and BCVA between 20/40 and 20/320, were included in this study. The biological activity was measured by alterations in BCVA as well as changes in the retinal thickness assessed by OCT. The results of this trial established that a single intravitreal injection of 4mg of aflibercept was well tolerated without any ocular toxicity. Its biologic activity was recognized by its role in improving BCVA and reducing retinal thickness. The median BCVA was 36 letters at baseline, and the median improvement seen was 9 letters after 4 wk and 3 letters after 6 wk. The median excess central 1mm foveal thickness (FTH) was 108µm at baseline, which was reduced to 59 µm at 4 wk and 74 µm at 6 wk after injection. Four of the five patients maintained the improvement in excess FTH (median 74 mm; 31% reduction from baseline, *P =* 0.0625) at 6 wk after injection.

Based on the results of the phase I study, a 52-week, multicenter, randomized, double-masked, active-controlled phase II clinical trial was conducted. The primary aim of the DME and VEGF Trap-Eye: INvestigation of Clinical Impact (DA VINCI) Study was to assess the safety and efficacy of intravitreal aflibercept in comparison with focal/grid laser photocoagulation in patients with DME. Diabetic patients who were ≥ 18 years old, with central retinal thickness (CRT) ≥ 250µm in the central subfield based on Stratus® OCT and with a BCVA between 20/40 and 20/320 were included in this study. Important study exclusion criteria were: history of vitreoretinal surgery, panretinal or macular laser photocoagulation within 3 mo of screening, use of intraocular or periocular corticosteroids within 3 mo of screening and uncontrolled diabetes mellitus or hypertension.

In the DA VINCI study, a total of 221 patients with DME from 39 sites in the United States, Canada, and Austria were randomly assigned in a 1:1:1:1:1 ratio to one of 5 treatment regimens in one eye only: 0.5mg aflibercept every 4 wk (0.5q4); 2 mg aflibercept every 4 wk (2q4); 2mg aflibercept for 3 initial monthly doses and then every 8 wk (2q8); 2 mg aflibercept for 3 initial monthly doses and then on an as-needed (PRN) basis (2PRN); or macular laser photocoagulation as specified by the modified ETDRS protocol. Assessments were done at baseline and every 4 wk thereafter.

The primary end point results of the DA VINCI study (week 24) revealed that treatment with intravitreal aflibercept produced a statistically significant improvement in VA when compared with macular laser treatment. The four aflibercept groups showed a greater mean BCVA gain and decrease in CRT in comparison to the laser group. [+8.5 to +11.4 ETDRS letters *vs* only +2.5 letters in the laser group (P ≤ 0.0085 for each aflibercept group *vs* laser) and +127.3 to +194.5 µm *vs* +67.9 µm (*P =*  0.0066 for each aflibercept group *vs* laser)]. It also showed that aflibercept was well tolerated and its ocular adverse events were consistent with those seen with other intravitreal anti-VEGF agents.

Recently, the DA VINCI study group has also published the results of different doses and dosing regimens of aflibercept with laser photocoagulation in eyes with DME after 52 wk. Assessment of the changes in BCVA and mean changes in CRT at 24 and 52 wk revealed that significant gains in BCVA from baseline, achieved at week 24, were maintained or improved at week 52 in all aflibercept groups. Mean BCVA increases in the aflibercept groups at week 52 were 11.0, 13.1, 9.7, and 12.0 letters *vs* −1.3 letters for the laser group (*P* ≤ 0.0001). Mean decrease in CRT in the aflibercept groups at week 52 were −165.4 μm, −227.4 μm, −187.8 μm, and −180.3 μm *vs* −58.4 μm for laser (*P <* 0.0001)[[34](#_ENREF_34)].

At one year, subjects who were treated with aflibercept in the DA VINCI study were doing well. The most frequently reported ocular adverse events associated with aflibercept use were conjunctival hemorrhage (18.9%), increased intraocular pressure (9.7%), eye pain (8.6%), ocular hyperemia (6.3%) and vitreous floaters (5.1%). Serious adverse effects included endophthalmitis (1.1%), uveitis (0.6%), corneal abrasion (0.6%) and retinal tear (0.6%). Systemic adverse events included hypertension (9.7%), cerebral vascular accidents (1.1%), and myocardial infarction (1.1%).

**ONGOING STUDIES**

Since the DA VINCI study was not powered sufficiently to uncover the potential systemic AEs or mortality related to aflibercept, additional phase-III clinical studies of aflibercept have been initiated. (Table 2)

***VIVID-Japan***

The Japanese Safety Study of VEGF Trap-Eye in DME (VIVID-Japan) is an open-label phase-III study evaluating the safety and tolerability of repeated doses of intravitreal VEGF Trap-Eye (BAY86-5321) in Japanese subjects with DME. Subjects in the aflibercept group will initially receive a loading phase consisting of injections given every 4 wk, followed by an injection every 8 wk. The overall treatment period is 48 wk[[35](#_ENREF_35)].

***VIVID-DME***

VEGF Trap-Eye in Vision Impairment Due to DME (VIVID-DME) was designed to determine the efficacy of intravitreal VEGF Trap-Eye (BAY86-5321) on the BCVA assessed by the ETDRS chart in subjects with DME with central involvement. This multi-central, randomized, double masked, active controlled, phase-III study of the efficacy and safety of repeated doses of intravitreal aflibercept in subjects with DME will assess changes from baseline of BCVA in ETDRS letter score over a 52 wk period in about 375 patients in 91 study locations. The treatment regimens will include 2 arms treated with aflibercept and one with laser therapy according to the ETDRS protocol[[36](#_ENREF_36)].

***VISTA DME***

Study of Intravitreal Administration of VEGF Trap-Eye (BAY86-5321) in Patients with Diabetic Macular Edema (VISTA DME) will assess the efficacy of 2 different dosing regimens of aflibercept compared with laser over the course of 2-year period. VISTA DME is a double-masked, randomized, active-controlled, phase-III study of the efficacy and safety of intravitreal aflibercept in 466 subjects with DME in 52 study locations[[37](#_ENREF_37)].

***Protocol T***

This phase III study sponsored by the Diabetes Clinical Research Network will compare the safety and efficacy of intravitreal aflibercept (2.0 mg), bevacizumab (1.25 mg) and ranibizumab (0.5 mg) for DME in 660 patients recruited from different clinical centers in the US. The primary outcome in this study is to evaluate the changes in BCVA at month 12. Protocol T is currently recruiting patients[[38](#_ENREF_38)].

**ACKNOWLEDGMENTS**

Dr. Do and Dr. Nguyen serve on the Steering Committee for the study of VEGF Trap Eye/Aflibercept in Diabetic Macular Edema.

**REFERENCES**

1 **Tremolada G**, Lattanzio R, Mazzolari G, Zerbini G. The therapeutic potential of VEGF inhibition in diabetic microvascular complications. *Am J Cardiovasc Drugs* 2007; **7**: 393-8.

2 **Do DV**, Schmidt-Erfurth U, Gonzalez VH, Gordon CM, Tolentino M, Berliner AJ, Vitti R, Rückert R, Sandbrink R, Stein D, Yang K, Beckmann K, Heier JS. The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. *Ophthalmology* 2011; **118**: 1819-1826 [PMID: 21546089 DOI: 10.1016/j.ophtha.2011.02.018]

3 **Klein R**, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. *Ophthalmology* 1984; **91**: 1464-1474 [PMID: 6521986]

4 **Ding J**, Wong TY. Current epidemiology of diabetic retinopathy and diabetic macular edema. *Curr Diab Rep* 2012; **12**: 346-354 [PMID: 22585044 DOI: 10.1007/s11892-012-0283-6]

5 Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group. *Ophthalmology* 1987; **94**: 761-774 [PMID: 3658348]

6 Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. *Arch Ophthalmol* 1985; **103**: 1796-1806 [PMID: 2866759 DOI: 10.1001/archopht.1985.01050120030015]

7 **Kaiser PK**. Vascular endothelial growth factor Trap-Eye for diabetic macular oedema. *Br J Ophthalmol* 2009; **93**: 135-136 [PMID: 19174397 DOI: 10.1136/bjo.2008.144071]

8 **Grant MB**, Afzal A, Spoerri P, Pan H, Shaw LC, Mames RN. The role of growth factors in the pathogenesis of diabetic retinopathy. *Expert Opin Investig Drugs* 2004; **13**: 1275-1293 [PMID: 15461557 DOI: 10.1517/13543784.13.10.1275]

9 **Aiello LP**, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. *N Engl J Med* 1994; **331**: 1480-1487 [PMID: 7526212 DOI: 10.1056/NEJM199412013312203]

10 **Ozaki H**, Hayashi H, Vinores SA, Moromizato Y, Campochiaro PA, Oshima K. Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. *Exp Eye Res* 1997; **64**: 505-517 [PMID: 9227268 DOI: 10.1006/exer.1996.0239]

11 **Tolentino MJ**, McLeod DS, Taomoto M, Otsuji T, Adamis AP, Lutty GA. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. *Am J Ophthalmol* 2002; **133**: 373-385 [PMID: 11860975 DOI: 10.1016/S0002-9394(01)01381-2]

12 **Tolentino MJ**, Miller JW, Gragoudas ES, Jakobiec FA, Flynn E, Chatzistefanou K, Ferrara N, Adamis AP. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. *Ophthalmology* 1996; **103**: 1820-1828 [PMID: 8942877]

13 **Nishikiori N**, Osanai M, Chiba H, Kojima T, Mitamura Y, Ohguro H, Sawada N. Glial cell-derived cytokines attenuate the breakdown of vascular integrity in diabetic retinopathy. *Diabetes* 2007; **56**: 1333-1340 [PMID: 17470563 DOI: 10.2337/db06-1431]

14 **Gardner TW**, Antonetti DA, Barber AJ, LaNoue KF, Levison SW. Diabetic retinopathy: more than meets the eye. *Surv Ophthalmol* 2002; **47** Suppl 2: S253-S262 [PMID: 12507627 DOI: 10.1016/S0039-6257(02)00387-9]

15 **Ho AC**, Scott IU, Kim SJ, Brown GC, Brown MM, Ip MS, Recchia FM. Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema: a report by the American Academy of Ophthalmology. *Ophthalmology* 2012; **119**: 2179-2188 [PMID: 22917890 DOI: 10.1016/j.ophtha.2012.07.058]

16 **Wroblewski JJ**, Wells JA, Gonzales CR. Pegaptanib sodium for macular edema secondary to branch retinal vein occlusion. *Am J Ophthalmol* 2010; **149**: 147-154 [PMID: 19875087 DOI: 10.1016/j.ajo.2009.08.005]

17 **Cunningham ET**, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D'Amico DJ, Goldbaum M, Guyer DR, Katz B, Patel M, Schwartz SD. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. *Ophthalmology* 2005; **112**: 1747-1757 [PMID: 16154196 DOI: 10.1016/j.ophtha.2005.06.007]

18 A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema. (Accessed at http: //clinicaltrials.gov/ct2/show/NCT01100307?term=phase 3 trials for pegaptanib&rank=1.)

19 **Nguyen QD**, Tatlipinar S, Shah SM, Haller JA, Quinlan E, Sung J, Zimmer-Galler I, Do DV, Campochiaro PA. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. *Am J Ophthalmol* 2006; **142**: 961-969 [PMID: 17046701 DOI: 10.1016/j.ajo.2006.06.068]

20 **Nguyen QD**, Shah SM, Heier JS, Do DV, Lim J, Boyer D, Abraham P, Campochiaro PA. Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study. *Ophthalmology* 2009; **116**: 2175-81.e1 [PMID: 19700194]

21 **Nguyen QD**, Shah SM, Khwaja AA, Channa R, Hatef E, Do DV, Boyer D, Heier JS, Abraham P, Thach AB, Lit ES, Foster BS, Kruger E, Dugel P, Chang T, Das A, Ciulla TA, Pollack JS, Lim JI, Eliott D, Campochiaro PA. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. *Ophthalmology* 2010; **117**: 2146-2151 [PMID: 20855114 DOI: 10.1016/j.ophtha.2010.08.016]

22 **Nguyen QD**, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, Gibson A, Sy J, Rundle AC, Hopkins JJ, Rubio RG, Ehrlich JS. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. *Ophthalmology* 2012; **119**: 789-801 [PMID: 22330964 DOI: 10.1016/j.ophtha.2011.12.039]

23 **Rajendram R**, Fraser-Bell S, Kaines A, Michaelides M, Hamilton RD, Esposti SD, Peto T, Egan C, Bunce C, Leslie RD, Hykin PG. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. *Arch Ophthalmol* 2012; **130**: 972-979 [PMID: 22491395 DOI: 10.1001/archophthalmol.2012.393]

24 **Holash J**, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS. VEGF-Trap: a VEGF blocker with potent antitumor effects. *Proc Natl Acad Sci U S A* 2002; **99**: 11393-11398 [PMID: 12177445 DOI: 10.1073/pnas.172398299]

25 **Stewart MW**, Grippon S, Kirkpatrick P. Aflibercept. *Nat Rev Drug Discov* 2012; **11**: 269-270 [PMID: 22460118 DOI: 10.1038/nrd3700]

26 **Yung WK**. Moving toward the next steps in angiogenesis therapy? *Neuro Oncol* 2008; **10**: 939 [PMID: 18981258 DOI: 10.1215/15228517-2008-091]

27 **Stewart MW**, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. *Br J Ophthalmol* 2008; **92**: 667-668 [PMID: 18356264 DOI: 10.1136/bjo.2007.134874]

28 **Bakri SJ**, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). *Ophthalmology* 2007; **114**: 855-859 [PMID: 17467524 DOI: 10.1016/j.ophtha.2007.01.017]

29 **Stewart MW**. What are the half-lives of ranibizumab and aflibercept (VEGF Trap-eye) in human eyes? Calculations with a mathematical model. Eye Reports 2011; 1. PUBMED ID

30 EYLEA - aflibercept injection, solution. Regeneron Pharmaceuticals, Inc. . (Accessed at http: //dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=67921.)

31 **Do DV**, Nguyen QD, Shah SM, Browning DJ, Haller JA, Chu K, Yang K, Cedarbaum JM, Vitti RL, Ingerman A, Campochiaro PA. An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema. *Br J Ophthalmol* 2009; **93**: 144-149 [PMID: 19174400 DOI: 10.1136/bjo.2008.138271]

32 **Brown DM**, Heier JS, Ciulla T, Benz M, Abraham P, Yancopoulos G, Stahl N, Ingerman A, Vitti R, Berliner AJ, Yang K, Nguyen QD. Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration. *Ophthalmology* 2011; **118**: 1089-1097 [PMID: 21640257 DOI: 10.1016/j.ophtha.2011.02.039]

33 **Thai HT**, Veyrat-Follet C, Vivier N, Dubruc C, Sanderink G, Mentré F, Comets E. A mechanism-based model for the population pharmacokinetics of free and bound aflibercept in healthy subjects. *Br J Clin Pharmacol* 2011; **72**: 402-414 [PMID: 21575034 DOI: 10.1111/j.1365-2125.2011.04015.x]

34 **Do DV**, Nguyen QD, Boyer D, Schmidt-Erfurth U, Brown DM, Vitti R, Berliner AJ, Gao B, Zeitz O, Ruckert R, Schmelter T, Sandbrink R, Heier JS. One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema. *Ophthalmology* 2012; **119**: 1658-1665 [PMID: 22537617]

35 Japanese Safety Study of VEGF Trap-Eye in DME (Diabetic Macular Edema) (VIVID-Japan). (Accessed at http: //clinicaltrials.gov/ct2/show/NCT01512966?term=VIVID&rank=5.) PUBMED ID

36 VEGF Trap-Eye in Vision Impairment Due to DME (VIVID-DME). (Accessed at http: //clinicaltrials.gov/ct2/show/NCT01331681?term=VEGF Trap-Eye&rank=10.)

37 Study of Intravitreal Administration of VEGF Trap-Eye (BAY86-5321) in Patients With Diabetic Macular Edema (VISTA DME). (Accessed at http: //clinicaltrials.gov/ct2/show/NCT01363440?term=VEGF Trap-Eye&rank=22.)

38 Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for DME (Protocol T). (Accessed at http: //clinicaltrials.gov/ct2/show/NCT01627249?term=aflibercept for DME&rank=3.)

39 **Michaelides M**, Kaines A, Hamilton RD, Fraser-Bell S, Rajendram R, Quhill F, Boos CJ, Xing W, Egan C, Peto T, Bunce C, Leslie RD, Hykin PG. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. *Ophthalmology* 2010; **117**: 1078-1086.e2 [PMID: 20416952]

40 **Massin P**, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, Mitchell P, Sharp D, Wolf-Schnurrbusch UE, Gekkieva M, Weichselberger A, Wolf S. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. *Diabetes Care* 2010; **33**: 2399-2405 [PMID: 20980427 DOI: 10.2337/dc10-0493]

**P-Reviewer** Navea-Tejerina A **S-Editor** Wen LL  **L-Editor**  **E-Editor**

**Table 1 Summary of some important trials in which vascular endothelial growth factor antagonists have been evaluated for diabetic macular edema**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Drug Name** | **Pegaptanib** | **Bevacizumab** | **Ranibizumab** | | | | |
| **Study Name** | Study To Evaluate Safety And Tolerability Of Pegaptanib Sodium In Patients With Diabetic Macular Edema[39] | BOLT study[[23](#_ENREF_23), [39](#_ENREF_39)] | RESOLVE[[40](#_ENREF_40)] | READ-2[[21](#_ENREF_21), [20](#_ENREF_20), 43] | READ-3[44] | RISE[[22](#_ENREF_22)] | RIDE[[22](#_ENREF_22)] |
| **Study type/ Phase** | Interventional/ Phase 3 | Interventional/  Phase 2 | Interventional/  Phase 2 | Interventional/  Phase 2 | Interventional/  Phase 2 | Interventional/Phase 3 | Interventional/ Phase 3 |
| **Number of patients** | 46 | 80 | 151 | 126 | 142 | 377 | 382 |
| **Intervention/**  **Study design** | 0.3 mg injections up to a maximum of 48 wk with a minimum-dosing interval of at least 6 wk. | a) Intravitreal Bevacizumab  b) Macular laser therapy (MLT) | a) 0.3 mg Ranibizumab  b) 0.5 mg Ranibizumab  c) Sham | a) 0.5 mg ranibizumab (group 1)  b) Focal/grid laser (group 2)  c) 0.5 mg ranibizumab + focal/grid laser (group 3). | a) 0.5 mg ranibizumab  b) 2 mg ranibizumab | a) Sham  b) 0.3 mg  c) 0.5 mg | a) Sham  b) 0.3 mg  c) 0.5 mg |
| **Results** | No results available yet. | Year 1 endpoint: A median gain of 8 ETDRS letters in the bevacizumab group *vs* a loss of 0.5 ETDRS letters in the MLT group (*P =* 0.0002). Central macular thickness (CMT) decreased from 507±145 μm to 378 ±134 μm (*P <*  0.001) in the bevacizumab group, whereas it decreased from 481±121 μm to 413±135 μm in the MLT group (*P =* 0.02)[[39](#_ENREF_39)  Year 2 endpoint: A Mean gain of 8.6 letters for bevacizumab *vs* a mean loss of 0.5 letters in the MLT group[ 23]. A mean reduction of 146 um in the CMT in the bevacizumab arm *vs* 118 μm in the MLT arm. | A gain of 10.3±9.1 letters with ranibizumab and a loss of 1.4±14.2 letters in the sham group (*P <* 0.0001).  A mean CMT reduction of 194.2±135.1 μm with ranibizumab and 48.4±153.4 μm with sham (*P <* 0.0001).  A gain of ≥ 10 letters in BCVA from baseline in 60.8% of eyes in the ranibizumab group and 18.4% of eyes in the sham group (*P <* 0.0001) | The mean improvement in BCVA was 7.4, 0.5, and 3.8 letters at the 6-month primary end point, compared with 7.7, 5.1, and 6.8 letters at month 24 in group 1, group 2 and group 3 respectively. The percentage of patients who gained 3 lines or more of BCVA was 21, 0, and 6 at month 6, compared with 24, 18, and 26 at month 24. Mean foveal thickness (FTH), defined as center subfield thickness, at month 24 was 340 μm, 286 μm, and 258 μm for groups 1, 2, and 3, respectively | The study is currently recruiting patients. | Year 2 endpoint:  18.1% of sham patients gained ≥15 letters *vs* 44.8% of 0.3-mg (*P <* 0.0001) and 39.2% of 0.5-mg ranibizumab patients (*P <* 0.001) | 12.3% of sham patients *vs* 33.6% of 0.3-mg patients (*P <* 0.0001) and 45.7% of 0.5-mg ranibizumab patients (*P <* 0.0001) gained more than 15 letters.  Significant improvements in macular edema.  Retinopathy was less likely to worsen and more likely to improve. |

DME: Diabetic macular edema; MLT: Macular laser therapy; FTH: Foveal thickness.

**Table 2 Summary of clinical trials in which aflibercept was evaluated for diabetic macular edema**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Study Name** | | **Phase 1 Study of VEGF Trap in Patients With DME** | **DA VINCI** | **VIVID-Japan** | **VISTA DME** | **VIVID-DME** | **Protocol T** |
| Study Type | | Interventional | Interventional | Interventional | Interventional | Interventional | Interventional |
| Study Phase | | Phase 1 | Phase 2 | Phase 3 | Phase 3 | Phase 3 | Phase 3 |
| Official title | | An Exploratory Study of the Safety, Tolerability and Biological Effect of a Single Intravitreal Administration of VEGF Trap Eye in Patients With DME | A Double-Masked, Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap-Eye in Patients With DME. | A Randomized, Double Masked, Active Controlled, Phase III Study of the Efficacy and Safety of Repeated Doses of Intravitreal VEGF Trap-Eye in Subjects With DME. | A Double- Masked, Randomized, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients With DME. | An Open-label Phase III Study Evaluating the Safety and Tolerability of Repeated Doses of Intravitreal VEGF Trap-Eye in Japanese Subjects With DME. | A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for DME. |
| Study Design | **Allocation** | Non-Randomized | Randomized | Randomized | N/A | Randomized | Randomized |
| **Endpoint Classification** | Safety Study | Safety/Efficacy Study | Safety/Efficacy Study | Safety/Efficacy Study | Safety/Efficacy Study | Safety/Efficacy Study |
| **Intervention Model** | Single Group Assignment | Parallel Assignment | Parallel Assignment | Single Group Assignment | Parallel Assignment | Parallel Assignment |
| **Masking** | Open Label | Double Blind (Subject, Investigator, Outcomes Assessor) | Double Blind (Subject, Investigator, Outcomes Assessor) | Open Label | Double Blind (Subject, Investigator, Outcomes Assessor) | Single Blind (Subject) |
| **Primary Purpose** | Treatment | Treatment | Treatment | Treatment | Treatment | Treatment |
| Enrollment | | 5 | 219 | 65 | 466 | 406 | 660 |
| Study Period | | 6 week | 52 week | 48 week | 2 year | 52 week | 2 year |
| Recruitment status | | Completed | Completed | Recruiting | Active, not recruiting | Active, not recruiting | Not yet recruiting |
| Primary Outcome Measure | | To assess the ocular and systemic safety and tolerability of a single IVT injection of VEGF Trap-Eye in patients with DME | Change in BCVA | Adverse Event collection | Change from baseline of BCVA in ETDRS letter score | Change from baseline of BCVA in ETDRS letter score | Change in visual acuity from baseline to one year adjusted for baseline visual acuity. |
| Estimated Study Completion Date | | Completed | Completed | Sep-13 | Nov-14 | Mar-15 | Jan-16 |